DiaMedica Therapeutics Inc. (DMAC) Stock

DiaMedica Therapeutics Inc. (DMAC) is a Healthcare stock trading at $6.51 (as of 2026-08-21), with a market capitalization of $351.06M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company developing treatments for neurological and kidney diseases. Its pipeline includes DM199, a recombinant human tissue kallikrein-1 protein in Phase 2 trials for chronic kidney disease associated with diabetes and Phase 2/3 trials for acute ischemic stroke, and DM300 in pre-clinical development for inflammatory diseases.

Understand DiaMedica Therapeutics Inc.: how it makes money

DiaMedica Therapeutics develops clinical-stage treatments for neurological and kidney diseases, including its lead DM199 recombinant human tissue kallikrein-1 protein in Phase 2 REDUX for chronic kidney disease and Phase 2/3 REMEDy2 for acute ischemic stroke, and it makes money primarily through future commercialization, while currently it is focused on advancing these trials (no revenue reported).

With no reported revenue, the profit engine is the clinical development path for DM199 and DM300, where trial execution and progression (enrollment, site activation, and interim analysis thresholds) drive whether development can continue or be halted.

Business quality (Weak): Limited company-level breakdown provided, and revenue is reported as 0.0B, so the investment case and operating visibility rely heavily on trial and enrollment milestones rather than segment performance.

Bull case

Two active clinical efforts for the same lead program: DM199 is in Phase 2 REDUX for moderate or severe chronic kidney disease in patients with Type I or Type II diabetes, and in Phase 2/3 REMEDy2 for acute ischemic stroke.
Clear execution indicators for REMEDy2: The company reports trial enrollment progress metrics, including ReMEDy2 Trial Enrollment as Percent of Required Enrollment and specific interim analysis patient thresholds.
Pipeline expansion beyond DM199: DM300 is in pre-clinical stage for inflammatory diseases.

Bear case

No reported revenue: Revenue is reported as 0.0B (as of 2026-03-31), consistent with a clinical-stage biopharmaceutical company that may not have near-term product income.
Significant operating losses: Operating margin is reported as -2230.2 (as of 2026-03-31), which highlights ongoing cost pressure before any commercialization.
Clinical trial outcomes can force decisions at interim analyses: The company reports interim analysis thresholds, including an Interim Analysis Termination Threshold Versus Placebo, which implies the program could be stopped based on results.

Valuation — source: SEC EDGAR (first-party)
Price	$6.51
Market Cap	$351.06M
Price / Book	9.16
Price / Sales	207.36
FCF Yield	-16.2%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$1.67M
Net Margin	-1963.2%
Revenue Growth (YoY)	-27.5%
EPS Growth (YoY)	16.7%
FCF Growth (YoY)	31.7%

Financial Health — source: SEC EDGAR
Altman Z-Score	35.33 (safe)

Valuation vs Sector & Industry
Sector P/E (Healthcare)	21.7
Industry P/E (Pharmaceutical Products)	17.2

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	COOPERMAN LEON G ($13.68M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Dietrich John Pauls
Employees	27
Country	US
IPO Date	2012-08-03

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.